Who
Brett R. Hagen
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Kalaris Therapeutics; Principal Accounting Officer, Proteostasis Therapeutics.
In numbers
- Trades disclosed
- 74
- Buys
- 0
- Sells
- 50
- Bought
- $0
- Sold
- $741K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 4 Aug 2016
- Last trade
- 20 Mar 2026
- Last filed
- 23 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Mar 2026filed 23 Mar 2026 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K1,915 at $6.72 | filing |
| 20 Mar 2026filed 23 Mar 2026 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K1,915 at $6.72 | filing |
| 19 Mar 2026filed 23 Mar 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,800 at $0.00 | filing |
| 19 Mar 2026filed 23 Mar 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,800 at $0.00 | filing |
| 10 Apr 2025filed 11 Apr 2025 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,262 at $0.00 | filing |
| 26 Mar 2025filed 27 Mar 2025 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,136907 at $8.97 | filing |
| 21 Feb 2025filed 24 Feb 2025 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $96896 at $10.08 | filing |
| 23 Jan 2025filed 27 Jan 2025 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $30232 at $9.45 | filing |
| 23 Jan 2025filed 27 Jan 2025 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $404 at $9.94 | filing |
| 10 Jan 2025filed 13 Jan 2025 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $146332 at $0.44 | filing |
| 19 Nov 2024filed 20 Nov 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $305554 at $0.55 | filing |
| 5 Nov 2024filed 6 Nov 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,4231,655 at $0.86 | filing |
| 22 Oct 2024filed 23 Oct 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $374486 at $0.77 | filing |
| 21 Oct 2024filed 23 Oct 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $374479 at $0.78 | filing |
| 3 Oct 2024filed 4 Oct 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $244301 at $0.81 | filing |
| 19 Aug 2024filed 20 Aug 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $413544 at $0.76 | filing |
| 5 Aug 2024filed 7 Aug 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,2351,692 at $0.73 | filing |
| 22 Jul 2024filed 23 Jul 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $356481 at $0.74 | filing |
| 19 Jul 2024filed 23 Jul 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $359479 at $0.75 | filing |
| 2 Jul 2024filed 3 Jul 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Sold | $219304 at $0.72 | filing |
News
No headline names them, or the companies they trade most, lately.